title: Overcoming aromatase inhibitor resistance in breast cancer: possible mechanisms and clinical applications.
abstract: Estrogen plays crucial roles in the progression of hormone-dependent breast cancers through activation of nuclear estrogen receptor α (ER). Estrogen is produced locally from circulating inactive steroids and adrenal androgens in postmenopausal women. However, conversion by aromatase is a rate-limiting step in intratumoral estrogen production in breast cancer. Aromatase inhibitors (AIs) inhibit the growth of hormone-dependent breast cancers by blocking the conversion of adrenal androgens to estrogen and by unmasking the inhibitory effect of androgens, acting via the androgen receptor (AR). AIs are thus a standard treatment option for postmenopausal hormone-dependent breast cancer. However, although initial use of AIs provides substantial clinical benefit, some breast cancer patients relapse because of the acquisition of AI resistance. A better understanding of the mechanisms of AI resistance may contribute to the development of new therapeutic strategies and aid in the search for new therapeutic targets and agents. We have investigated AI-resistance mechanisms and established six AI-resistant cell lines. Some of them exhibit estrogen depletion-resistance properties via constitutive ER-activation or ER-independent growth signaling. We examined how breast cancer cells can adapt to estrogen depletion and androgen superabundance. Estrogen and estrogenic androgen produced independently from aromatase contributed to cell proliferation in some of these cell lines, while another showed AR-dependent cell proliferation. Based on these findings, currently proposed AI-resistance mechanisms include an aromatase-independent estrogen-producing pathway, estrogen-independent ER function, and ER-independent growth signaling. This review summarizes several hypotheses of AI-resistance mechanisms and discusses how existing or novel therapeutic agents may be applied to treat AI-resistant breast cancers.
authors.affiliation: Division of Breast and Endocrine Surgery, Department of Surgery, Shinshu University School of Medicine, 3-1-1 Asahi, Matsumoto, Nagano, Japan.|Department of Surgery, Japanese Red Cross Society Suwa Hospital, 5-11-50 Kogandori, Suwa, Nagano, Japan.
authors.forename: Toru
authors.initials: T
authors.lastname: Hanamura
authors.affiliation: Center for Regulatory Epigenome and Diseases, Department of Molecular and Functional Dynamics, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan. shin@med.tohoku.ac.jp.
authors.forename: Shin-Ichi
authors.initials: SI
authors.lastname: Hayashi
mesh_terms: D047072:Aromatase Inhibitors / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D045744:Cell Line, Tumor; D051358:Cyclin-Dependent Kinase 4 / Q000378:metabolism; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D005260:Female; D006801:Humans; D017698:Postmenopause; D011944:Receptors, Androgen / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism
chemical_list: C410798:AR protein, human; D047072:Aromatase Inhibitors; D011944:Receptors, Androgen; D011960:Receptors, Estrogen; C495900:CDK4 protein, human; D051358:Cyclin-Dependent Kinase 4
keywords: Androgen; Aromatase inhibitor resistance; Breast cancer; Estrogen